Fulcrum Therapeutics, Inc. Common Stock (FULC)
PHARMACEUTICAL PREPARATIONS
Fulcrum Therapeutics, Inc. Common Stock (FULC) is listed on Nasdaq, where it has traded since July 18, 2019.
- Listed On
- Nasdaq
- Listed Since
- July 18, 2019
- Employees
- 55
- Market Cap
- $281M
About Fulcrum Therapeutics, Inc. Common Stock
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 149 institutions reported holding FULC, with 79.3 million shares worth $290.5 million in aggregate. The largest reported holder was BlackRock, with 8.8 million shares worth $32.3 million. Of the 5 largest holders listed below, 2 opened new positions in FULC and 3 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 8,824,259 | $32M | Added 63.7% |
| Ecor1 Capital | 6,549,866 | $24M | New position |
| Tang Capital Management | 6,521,412 | $24M | New position |
| Nantahala Capital Management | 5,475,040 | $20M | Added 79.51% |
| Vanguard | 3,859,119 | $14M | Added 4.96% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is FULC?
Fulcrum Therapeutics, Inc. Common Stock (FULC) is listed on Nasdaq, where it has traded since July 18, 2019.
Who are the largest institutional holders of FULC?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of FULC were BlackRock, Ecor1 Capital and Tang Capital Management.
How many institutions own FULC?
149 institutions reported a position in FULC for the quarter ended June 30, 2026, worth $290.5 million in total.
Did institutions buy or sell FULC last quarter?
Of the 5 largest reported holders, 2 opened new positions in FULC and 3 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for FULC.
Every reported institutional holder, plus insider and congressional trades in FULC, on SentiSense.